Aridis Pharmaceuticals, Inc. | Business Contracts

Form of Securities Purchase Agreement (Filed With SEC on March 15, 2023)

At-the-Market Sales Agreement, dated January 19, 2022 by and between the Company and Virtu Americas LLC (Filed With SEC on January 19, 2022)

Amendment No. 1 to the License Agreement between Medimmune Limited and Aridis Pharmaceuticals, Inc. dated August 9, 2021 (Filed With SEC on August 12, 2021)

Office Lease dated October 14, 2020 by and between Aridis Pharmaceuticals, Inc. and Boccardo Corporation (Filed With SEC on October 20, 2020)

Description of the Registrant's Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on April 8, 2020)

Form of Securities Purchase Agreement (Filed With SEC on December 12, 2022)

Form of Securities Purchase Agreement (Filed With SEC on October 5, 2022)

Form of Warrant (Filed With SEC on October 5, 2022)

Form of Pre-Funded Warrant (Filed With SEC on October 5, 2022)

Security Agreement dated as of November 23, 2021 (Filed With SEC on November 30, 2021)

Note Purchase Agreement dated as of November 23, 2021 (Filed With SEC on November 30, 2021)

Form of Secured Promissory Note (Filed With SEC on November 30, 2021)

Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on August 4, 2021)

Form of Securities Purchase Agreement (Filed With SEC on August 4, 2021)

Form of Common Stock Purchase Warrant (Filed With SEC on August 4, 2021)

License Agreement between Medimmune Limited and Aridis Pharmaceuticals, Inc. dated as of July 12, 2021 (Filed With SEC on July 19, 2021)

Form of Securities Purchase Agreement, dated March 15, 2021, by and between Aridis Pharmaceuticals, Inc. and the Purchasers (Filed With SEC on March 15, 2021)

Exclusive License Agreement dated September 10, 2020 by and between Aridis Pharmaceuticals, Inc. and UAB Research Foundation (Filed With SEC on November 23, 2020)

Form of Series B Warrant (Filed With SEC on October 14, 2020)

Form of Series A Warrant (Filed With SEC on October 14, 2020)

Form of Securities Purchase Agreement, dated October 13, 2020, by and between Aridis Pharmaceuticals, Inc. and the Purchasers (Filed With SEC on October 14, 2020)

License, Development and Commercialization Agreement between Aridis Pharmaceuticals, Inc. and Serum AMR Products, entered into as of September 27, 2019 (Filed With SEC on October 3, 2019)

Option Agreement for Exclusive Product and Platform Technology License between Aridis Pharmaceuticals, Inc. and Serum International BV, dated July 16, 2019 (Filed With SEC on July 30, 2019)

Stock Subscription Agreement, dated July 19, 2019 (Filed With SEC on July 30, 2019)

Amendment No. 1 to the Agreement between the Registrant and the Cystic Fibrosis Foundation Therapeutics, Inc., effective November 26, 2018 (Filed With SEC on March 28, 2019)

Aridis Pharmaceuticals, Inc. (25)